Child Nutrition Research Centre, Women's and Children's Health Research Institute, Women's and Children's Hospital, 72 King William Rd, North Adelaide SA 5006, Australia.
JAMA. 2010 Oct 20;304(15):1675-83. doi: 10.1001/jama.2010.1507.
Uncertainty about the benefits of dietary docosahexaenoic acid (DHA) for pregnant women and their children exists, despite international recommendations that pregnant women increase their DHA intakes.
To determine whether increasing DHA during the last half of pregnancy will result in fewer women with high levels of depressive symptoms and enhance the neurodevelopmental outcome of their children.
DESIGN, SETTING, AND PARTICIPANTS: A double-blind, multicenter, randomized controlled trial (DHA to Optimize Mother Infant Outcome [DOMInO] trial) in 5 Australian maternity hospitals of 2399 women who were less than 21 weeks' gestation with singleton pregnancies and who were recruited between October 31, 2005, and January 11, 2008. Follow-up of children (n = 726) was completed December 16, 2009.
Docosahexaenoic acid-rich fish oil capsules (providing 800 mg/d of DHA) or matched vegetable oil capsules without DHA from study entry to birth.
High levels of depressive symptoms in mothers as indicated by a score of more than 12 on the Edinburgh Postnatal Depression Scale at 6 weeks or 6 months postpartum. Cognitive and language development in children as assessed by the Bayley Scales of Infant and Toddler Development, Third Edition, at 18 months.
Of 2399 women enrolled, 96.7% completed the trial. The percentage of women with high levels of depressive symptoms during the first 6 months postpartum did not differ between the DHA and control groups (9.67% vs 11.19%; adjusted relative risk, 0.85; 95% confidence interval [CI], 0.70-1.02; P = .09). Mean cognitive composite scores (adjusted mean difference, 0.01; 95% CI, -1.36 to 1.37; P = .99) and mean language composite scores (adjusted mean difference, -1.42; 95% CI, -3.07 to 0.22; P = .09) of children in the DHA group did not differ from children in the control group.
The use of DHA-rich fish oil capsules compared with vegetable oil capsules during pregnancy did not result in lower levels of postpartum depression in mothers or improved cognitive and language development in their offspring during early childhood.
anzctr.org.au Identifier: ACTRN12605000569606.
尽管国际建议孕妇增加 DHA 摄入量,但关于 DHA 对孕妇及其子女益处的不确定性仍然存在。
确定在妊娠最后半个月增加 DHA 是否会减少出现高抑郁症状水平的女性数量,并改善其子女的神经发育结局。
设计、地点和参与者:这是一项在澳大利亚 5 家产科医院进行的、有 2399 名单胎妊娠且孕周不足 21 周的女性参与的、双盲、多中心、随机对照试验(DHA 以优化母婴结局[DOMInO]试验)。这些女性于 2005 年 10 月 31 日至 2008 年 1 月 11 日入组,随访儿童(n=726)于 2009 年 12 月 16 日完成。
从入组到分娩,给予富含二十二碳六烯酸(DHA)的鱼油胶囊(提供 800mg/d 的 DHA)或不含 DHA 的匹配植物油胶囊。
产后 6 周或 6 个月时,母亲的爱丁堡产后抑郁量表评分>12 分,表示出现较高水平的抑郁症状。
在入组的 2399 名女性中,96.7%完成了试验。产后前 6 个月出现高抑郁症状的女性比例,DHA 组与对照组之间无差异(9.67%vs11.19%;调整后的相对风险,0.85;95%置信区间[CI],0.70-1.02;P=0.09)。DHA 组儿童的认知综合评分(调整后的平均差异,0.01;95%CI,-1.36 至 1.37;P=0.99)和语言综合评分(调整后的平均差异,-1.42;95%CI,-3.07 至 0.22;P=0.09)与对照组儿童无差异。
与使用植物油胶囊相比,在妊娠期间使用富含 DHA 的鱼油胶囊并不能降低母亲产后的抑郁水平,也不能改善其子女在幼儿期的认知和语言发育。
anzctr.org.au 标识符:ACTRN12605000569606。